Author Query Form Journal Title Article Number
: :
ANG 512558
Dear Author/Editor, Greetings, and thank you for publishing with SAGE Publications. Your article has been copyedited, and we have a few queries for you. Please address these queries when you send your proof corrections to the production editor. Thank you for your time and effort. Please assist us by clarifying the following queries:
No.
Query
1.
Please (a) check that all authors are listed in the proper order; (b) clarify which part of each author’s name is his or her surname; and (c) verify that all author names are correctly spelled/punctuated and are presented in a manner consistent with any prior publications.
2.
Please provide department name (if any) for affiliation 1 and in the correspondence field.
Remarks
Letter to the Editor
Proprotein Convertase Subtilisin/Kexin Type 9: A Plausible Link Between Serum Resistin Levels and Cardiovascular Events AQ 1
Angiology 201X, Vol XX(X) 1 ª The Author(s) 2013 Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/0003319713512558 ang.sagepub.com
Umit Yasar Sinan1
I read the letter by Sahebkar1 proposing ‘‘a link between serum resistin levels and cardiovascular events.’’ Sahebkar1 suggests that a positive correlation between serum levels of resistin and the severity of coronary artery disease (CAD) could be an attenuated response to statin therapy in patients with higher serum resistin levels, thereby causing an increased susceptibility to atherosclerosis. The author discussed some studies that support this concept. In our study,2 96 (58.5%) of the 164 patients in the CAD(þ) group and 18 (36%) of the 50 patients in the control group had hyperlipidemia (P ¼ .006). The use of statins was higher in the CAD(þ) group than that in the control group. However, the mean low-density lipoprotein cholesterol (LDL-C) levels were similar in 2 groups (122 + 34 mg/dL in the CAD(þ) group and 124 + 34 mg/dL in the control group). Although we do not have information regarding the statin doses used in each group, we would have expected lower mean LDL-C levels in the CAD group because of higher statin use.
In conclusion, we do not have enough information to substantiate whether elevated resistin levels are associated with a poorer response to statin therapy. As Sahebkar1 suggests, large-scale clinical end point statin trials should consider post hoc analyses in order to elucidate whether the efficacy of statin therapy in reducing cardiovascular outcomes varies between different subgroups stratified by serum resistin levels. References 1. Sahebkar A. Proprotein convertase subtilisin/kexin type 9: a plausible link between serum resistin levels and cardiovascular events. Angiology. IN PRESS. 2. Sinan UY, Canbolat IP, Baydar O, et al. Relationship between increased serum resistin level and severity of coronary artery disease. Angiology. IN PRESS.
1
Viransehir State Hospital, Sanlıurfa, Turkey
Corresponding Author: Umit Yasar Sinan, Viransehir State Hospital, Viransehir 63700, Sanlıurfa, Turkey. Email:
[email protected]
AQ 2